Marinus Pharma Q1 2024 GAAP EPS $(0.68) Misses $(0.66) Estimate, Sales $7.679M Miss $9.125M Estimate
Marinus Pharma Q1 2024 GAAP EPS $(0.68) Misses $(0.66) Estimate, Sales $7.679M Miss $9.125M Estimate
Marinus Pharma 2024年第一季度GAAP每股收益美元（0.68美元）未達到預期（0.66美元），銷售額爲767.9萬美元，未達到912.5萬美元的預期
Marinus Pharma (NASDAQ:MRNS) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.66) by 3.03 percent. This is a 1.49 percent decrease over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $7.679 million which missed the analyst consensus estimate of $9.125 million by 15.85 percent. This is a 26.02 percent decrease over sales of $10.380 million the same period last year.
Marinus Pharma（納斯達克股票代碼：MRNS）公佈的季度虧損爲每股0.68美元，比分析師普遍預期的0.66美元（0.66美元）低3.03個百分點。這比去年同期每股虧損0.67美元（0.67美元）下降了1.49％。該公司公佈的季度銷售額爲767.9萬美元，比分析師普遍預期的912.5萬美元低15.85％。這比去年同期的103.8億美元的銷售額下降了26.02％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。